This is an open-label, multi-center, single group, Phase 3 study for treatment with rilzabrutinib.
The purpose of this study is to provide continuation of rilzabrutinib treatment to adult participants with ITP who have completed the LTE of the LUNA 3 study in Japan, demonstrating clinically meaningful benefit as judged by the Investigator.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-09.
Status change: Not Yet Recruiting → Active, Not Recruiting2025-11-04